Molecular Partners (MOLN) Q4 2024 Earnings Report

57 Followers

Previous Report: Q2 2024

Next Report: Q2 2025

MOLN Q4 2024 EPS Results

Actual EPS-$0.36

Consensus EPS-$0.45

Beat/MissBeat by +$0.09

One Year Ago EPS-$0.68

MOLN Q4 2024 Revenue Results

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth-100.00%

Earnings Announcement Details

QuarterQ4 2024

Date03/06/2025

TimeAfter Close

Conference CallThursday, March 6, 2025

MOLN Upcoming Earnings

Molecular Partners's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q4 2024 Earnings Call Audio

MOLN Q4 2024 Earnings Call

0:00 / 0:00

Q4 2024 Earnings Slide Deck

Q4 2024 Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 06, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in Molecular Partners' programs, particularly in the radio DARPin franchise and the improved efficacy of the 533-DARPIn program. The expansion of the Orano Med collaboration and strong financial position further bolster the company's outlook. However, the discontinuation of the Novartis collaboration and initial challenges with the T Cell Engager program were noted as setbacks. Overall, the highlights significantly outweigh the lowlights.

Company Guidance

During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several key metrics and strategic developments were highlighted. The company reported operating expenses of CHF 66 million for the year, which was within their guidance range of CHF 65 million to CHF 70 million. They ended the year with a cash balance of CHF 149 million, having raised CHF 20 million in a financing round in October, and reported a cash burn of approximately CHF 54 million for the year. This funding positions them well financially, with a runway extending into 2027. Revenue for 2024 was CHF 5 million, primarily from their collaboration with Novartis, which has now concluded. The company is advancing its radio DARPin program, with their lead candidate MP0712 set to begin clinical trials and dosimetry studies in 2025. The expansion of their collaboration with Orano Med was also a significant milestone, securing access to 10 product slots for the promising isotope Lead-212. Additionally, Molecular Partners is continuing to refine its T cell engager platform, with plans to densify dosing schedules and further investigate premedication strategies in upcoming trials.

Successful Year of Execution

Molecular Partners successfully executed their plans in 2024, advancing programs toward clinical readouts and expanding their collaboration with Orano Med.

Lead DARPin Program Progress

The radio DARPin franchise showed significant progress with the lead compound DLL3 targeting 712 passing all IND-enabling studies and ready to enter clinical trials.

Strategic Collaboration with Orano Med

Molecular Partners expanded their collaboration with Orano Med to secure isotope supply for 10 products, enhancing their radio DARPin franchise.

Strong Financial Position

Ending the year with CHF149 million in cash, the company is well-capitalized with a runway into 2027, ensuring continued investment in their pipeline.

Improved Efficacy in T Cell Engager Program

The 533-DARPIn program for AML showed promising results with three complete responses out of eight patients after adjustments in dosing regimen.

MOLN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Mar 18, 2027	2026 (Q4)	- / -	-0.435	―
Aug 25, 2026	2026 (Q2)	-0.43 / -0.43	-0.686	36.73% (+0.25)
Mar 12, 2026	2025 (Q4)	-0.40 / -0.43	-0.363	-19.56% (-0.07)
Aug 25, 2025	2025 (Q2)	-0.47 / -0.69	-0.517	-32.69% (-0.17)
Mar 06, 2025	2024 (Q4)	-0.45 / -0.36	-0.678	46.46% (+0.32)
Aug 26, 2024	2024 (Q2)	- / -0.52	-0.978	47.14% (+0.46)
Mar 14, 2024	2023 (Q4)	-1.11 / -0.68	-1.077	37.05% (+0.40)
Aug 24, 2023	2023 (Q2)	-0.99 / -0.98	4.955	-119.74% (-5.93)
Mar 09, 2023	2022 (Q4)	-0.94 / -1.08	-0.979	-10.01% (-0.10)
Aug 25, 2022	2022 (Q2)	4.17 / 4.96	-1.117	543.60% (+6.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed